Alphamab Oncology Unveils Promising Clinical Data on Anti-HER2 Bispecific ADC Subcutaneous Co-formulation JSKN033 at SITC 2024

CAR-T Digest - August 2020

11 Nov 2024: Alphamab Oncology Unveils Promising Clinical Data on Anti-HER2 Bispecific ADC Subcutaneous Co-formulation JSKN033 at SITC 2024

Alphamab Oncology presented first-in-human results of JSKN033, a subcutaneous co-formulation combining an anti-HER2 bispecific ADC and PD-L1 inhibitor, at SITC 2024
JSKN033, developed with Envaforlimab (the first subcutaneously injectable PD-L1 inhibitor), aims to improve treatment safety and convenience by reducing infusion times and hospital stays
The ongoing Phase I/II study (JSKN033-101) is evaluating the safety and efficacy of JSKN033 in patients with advanced HER2-expressing tumors and HER2-mutant NSCLC
As of October 14, 2024, 11 patients were enrolled in the trial, with no dose-limiting toxicities and mild, self-limited injection site reactions
Preliminary data showed 80% disease control, including three partial responses, supporting further investigation of the ADC-immunotherapy combination